Corvus Pharmaceuticals, Inc. has initiated a Phase 1 clinical trial to evaluate soquelitinib in patients with moderate to severe atopic dermatitis. This trial, which is randomized, double-blind, and placebo-controlled,

Ocugen, Inc., a biotechnology firm specializing in the discovery, development, and commercialization of innovative gene and cell therapies, along with vaccines, has announced the approval of its Investigational New Drug

Dizal announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its drug sunvozertinib as the primary treatment for patients

IASO Biotechnology, a prominent biopharmaceutical company specializing in innovative cell therapy and antibody products, is excited to announce the approval of the Investigational New Drug application by the U.S. Food and Drug Administration

Basilea Pharmaceutica Ltd, based in Allschwil and traded on the SIX Swiss Exchange under the symbol BSLN, has announced that the US Food and Drug Administration has given approval for ZEVTERA®

Genmab A/S and ProfoundBio, Inc. have announced a definitive agreement today for Genmab's acquisition of ProfoundBio in an all-cash deal. ProfoundBio, a privately-owned clinical-stage biotechnology company, specializes in developing next-generation ADCs

Today, Scantox, along with its majority owner Impilo, has successfully concluded the acquisition of QPS Neuropharmacology, a leading contract research organization specializing in drug discovery for neurodegenerative diseases,

RemeGen Co. Ltd., a prominent biotechnology company, has recently secured Fast Track Designation from the United States Food and Drug Administration for its innovative drug Telitacicept

Xcell Biosciences Inc. recently expanded its collaboration with Labcorp, a prominent laboratory services provider, by incorporating new elements into their research agreement. In this enhanced partnership

Merz Therapeutics, a subsidiary of the Frankfurt-based Merz, has entered into an agreement to acquire two marketed drugs from the NASDAQ-listed US company Acorda Therapeutics. This deal is expected to significantly contribute to Merz Therapeutics' accelerated growth strategy.